Gregg Stone, Columbia University Medical Center, New York American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta A superiority for the anti-clotting drug bivalirudin for t
Gregg Stone, Columbia University Medical Center, New York
American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
A superiority for the anti-clotting drug bivalirudin for treating patients with acute coronary syndromes was detected when this was used as monotherapy, but not when this direct thrombin inhibitor was combined with glycoprotein IIb/IIIa inhibition. Thus found the ACUITY trial reported to the ACC’s Atlanta meeting by Gregg Stone of Columbia University. He told Audio Medica the bottom line finding from the study. [audio:https://www.audiomedica.com/podcasting/acc2006/gregg_stone.mp3]